Physician profile
Chellappan Vijayakumar
NPI 1457393167
$1,230.21
in general payments reported to CMS, 2019-2025
16 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.71 · 2021: $105 · 2022: $257 · 2023: $217 · 2024: $410 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $378.88 | 2022-2025 | |
| Irhythm Technologies, INC. | $260.68 | 2021-2024 | Zio Monitor, Zio Xt Patch |
| Astrazeneca Pharmaceuticals LP | $115.98 | 2022-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $105.56 | 2021-2024 | Eliquis |
| Medtronic Vascular, INC. | $65.71 | 2019 | |
| Philips North America LLC | $49.57 | 2023-2024 | (5050) Extended Holter |
| Janssen Pharmaceuticals, INC | $44.44 | 2023 | Xarelto |
| Esperion Therapeutics, INC. | $39.83 | 2022-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.12 | 2024 | Lifevest |
| Amgen INC. | $30.81 | 2025 | Repatha, Repatha |
| Heartflow, INC. | $29.28 | 2024 | |
| Scpharmaceuticals INC. | $17.31 | 2025 | |
| Pfizer INC. | $15.66 | 2023 | |
| Novo Nordisk INC | $15.57 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $14.43 | 2024 | Arcalyst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chellappan Vijayakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.